novartis_outside_1

Novartis’ Cosentyx gets European go-ahead in paediatric plaque psoriasis

pharmafile | August 3, 2020 | News story | Sales and Marketing Cosentyx, Europe, Novartis, pharma, psoriasis 

Novartis’ interleukin-17A (IL-17A) inhibitor Cosentyx (secukinumab) has chalked up approval from the European Commission (EC) for the treatment of patients between the ages of six and 18 with moderate-to-severe plaque psoriasis.

The ruling was secured on the back of data from two Phase 3 studies which demonstrated the safety and efficacy of low and high dosages (75-150mg and 75-300mg) in improving skin symptoms and quality of life. According to this latest approval, the recommended dose for children weighing up to 50 kg is 75 mg, and 150 mg for children 50 kg and over.

“Psoriasis is a life-long debilitating disease that significantly impacts children’s quality of life, both physically and emotionally. There are only a few approved treatment options available for the paediatric population and so it is important to broaden the adult therapeutic options out to children when possible,” said Professor Christine Bodemer, Head of the Department of Dermatology, Necker–Enfants Malades Hospital. “This approval means Cosentyx is now available in Europe for children and adolescents, and will provide an additional option to quickly gain relief from their symptom burden and to significantly improve their quality of life.”

Novartis said it was already at work in order to make the therapy available to eligible patients “as quickly as possible”.

Matt Fellows

Related Content

Novartis shares new data about Fabhalta for IgAN treatment

Novartis has announced new results from a pre-specified interim analysis of its phase 3 APPLAUSE-IgAN …

Boehringer Ingelheim’s Spevigo gains additional approvals in US and China

Boehringer Ingelheim has announced that Spevigo (spesolimab-sbzo) has been approved by the US Food and …

chuttersnap-oijvdm3zx4i-unsplash

Novartis shares new data for Zolgensma in children with SMA

Novartis has announced new data to continue the support of the clinical benefits of Zolgensma …

Latest content